- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03357939
Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects
A Phase 1 Randomized,Double-Blind and Parallel Controlled Single-dose Clinical Trial of Pharmacokinetics, Safety, Tolerability and Immunogenicity of HLX03 Compared With Humira® From China Source in Chinese Healthy Male Subjects
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a randomized, doubl-blinded, parellel-controlled phase 1 PK, safety, tolerability and immunogenicitiy study to compare HLX03, designed as an Adalimumab biosimilar, with China sourced Humira in Chinese health volunteers. All enrolled subjects will receive a single dose of HLX03 (40 mg)or Humira(adalimumab, 40 mg) in subcutaneous injectioin after randomization.
The purpose of this study to prove the similarity in PK, Safety, tolerability and immunogenicity beween HLX03(adalimumab biosimilar) and China sourced Humira and provide evidence for Phase III comparison study.
The blood will be collected before drug administration, and at 1 hr、4 hr、8 hr、24 hr (1d)、48 hr (2d)、72 hr (3d)、96 hr (4d)、、144 hr (6d)、192 hr (8d)、240 hr (10d)、 336 hr (14d)、504 hr (21d)、672 hr (28d)、840 hr (35d)、1008 hr (42d)、1176 hr (49d)、1344 hr (56d)、1680 hr (70d) after drug injection for PK, ADA, etc analysis. All subjects also will be followed up at 0, 1,2,3,4,6,8,10,14,21,28,35, 42, 49, 56, and 70 days after drug administration for AE and other specified outcomes.
The main endpoint is AUC from time zero to ∞. The second endpoints include Cmax, Tmax, T1/2, CL, Vd and AUC(0-last).
This is single center study in China.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Jilin
-
Chang Chun, Jilin, China
- the 1st affiliated hospital of Jilin University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy Chinese males (age: 18~45 yrs) with contraception during and 3 months post-dose. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination including blood pressure, pulse, ECG, and laboratory testing.
- BMI between 19.0 and 28.0 kg/m² and body weight between 55 kg and 80 kg.
Exclusion Criteria:
- suffering from active or latent tuberculosis or history of tuberculosis;
- have heart disease or a history of heart disease;
- suffer from mental illness or psychiatric history;
- suffering from malignant tumors and their history;
- suffering from herpes zoster and its history;
- suffering from epilepsy and history of epilepsy;
- be allergic to the drugs or its components with high sensitivity or allergic reaction, detection of ADA (+);
- patients who lost blood or donated more than 200 mL within the first 2 months before the screening;
- major surgery performed within 30 days prior to signing ICF;
- live vaccine inoculation or vaccination within 12 weeks of screening, or possible administration of vaccine during screening and study visits;
- previous application of adalimumab or its biosimilars, or anti-TNF alpha drugs;
- participating in other clinical trials within the first 3 months of the trial;
- abnormal immune function within 4 weeks before screening;
- the presence of invasive systemic fungal infection or other opportunistic infections within 2 months prior to screening;
- systemic or local infection, such as the risk of sepsis and / or known active inflammation within 2 months before screening;
- 2 months before the screening, there were severe infections in the hospital and / or the need for intravenous antibiotics;
- 4 or more upper respiratory tract infections occurred within 6 months prior to randomization;
- hepatitis B surface antigen (HBsAg) positive; if hepatitis B surface antigen (HBsAg) negative, hepatitis B core antibody (HBcAb) positive, peripheral blood hepatitis B virus deoxyribonucleic acid (DNA) test >0 IU/ml also ruled out;
- hepatitis C virus (HCV) antibody positive;
- human immunodeficiency virus (HIV) antibody positive;
- Treponema pallidum (Treponema pallidum, TP) antibody positive;
- anti nuclear antibody titer was 1:100 examination;
- drug abusers, alcohol addicts;
- , the researchers discretion of failure to follow the requirements of the program, instructions and research limitations, such as uncooperative attitude, unable to return to the Research Center for follow-up visits, or unable to complete the entire clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HLX03
There are about 68 subjects in this group will receive a single dose of 40 mg of HLX03 in 0.8 mL in subcutaneous injection.
|
A single dose of 40 mg HLX03 in 0.8 mL in subcutaneous injection.
Other Names:
|
Active Comparator: Humira
There are about 68 subjects in this group will receive a single dose of 40 mg of Humira in a pre-filled syringe in subcutaneous injection.
|
A single dose of 40 mg Humira in 0.8 mL in a pre-filled syringe
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Maximum Concentration(Cmax) of Adalimumab After Single SC Injection of HLX03/Humira
Time Frame: 71 days post-dose
|
71 days post-dose
|
Area Under the Plasma Concentration-time Curve From Zero (0) Hours to the last quantifiable concentration
Time Frame: 71 days post-dose
|
71 days post-dose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area Under the Plasma Concentration-time Curve From Zero (0) to Time Infinity
Time Frame: 71 days post-dose
|
71 days post-dose
|
Time to Maximum Concentration(Tmax) of Adalimumab After Single SC Injection
Time Frame: 71 days post-dose
|
71 days post-dose
|
Half-life time of adalimumab after single SC injection of HXL03/Humira
Time Frame: 71 days
|
71 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Yanhua Ding, MD, The 1st affiliated hospital, Jilin University, PRC
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HLX03-HV01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune System Disorder
-
Kadmon, a Sanofi CompanyCompletedImmune System Disorder (Healthy Volunteers)United States
-
Kadmon, a Sanofi CompanyCompletedImmune System Disorder (Healthy Volunteer)United States
-
Kadmon, a Sanofi CompanyCompletedImmune System Disorder (Healthy Volunteer)United States
-
Kadmon, a Sanofi CompanyCompletedImmune System Disorder (Healthy Volunteer)United States
-
University of HelsinkiTampere UniversityCompletedImmune System DisordersFinland
-
SanofiTerminatedImmune System DisorderUnited States, Spain
-
Universitätsklinikum Hamburg-EppendorfRecruitingPregnancy | Immune System DisorderGermany
-
University of New MexicoRecruitingDNA Damage | Immune System DisorderUnited States
-
Cairo UniversityRecruiting
-
Xiangya Hospital of Central South UniversityUnknownSepsis | Inflammatory Disorder of Immune System
Clinical Trials on HLX03
-
Shanghai Henlius BiotechCompletedPlaque PsoriasisChina